AR003102A1 - ENV-GLYCOPROTEIN VACCINE FOR THE PROTECTION OF HTLV-I AND II INFECTION - Google Patents
ENV-GLYCOPROTEIN VACCINE FOR THE PROTECTION OF HTLV-I AND II INFECTIONInfo
- Publication number
- AR003102A1 AR003102A1 ARP970103292A ARP970103292A AR003102A1 AR 003102 A1 AR003102 A1 AR 003102A1 AR P970103292 A ARP970103292 A AR P970103292A AR P970103292 A ARP970103292 A AR P970103292A AR 003102 A1 AR003102 A1 AR 003102A1
- Authority
- AR
- Argentina
- Prior art keywords
- htlv
- present
- env protein
- relates
- protein
- Prior art date
Links
Abstract
La presente invención se refiere a novedosos antígenos de proteina derivadas de la proteína HTLV env, que son capaces de ser utilizados comovacunas para ayudar en la prevención y tratamiento de las infecciones por HTLV- I y HTLV-II,y anoved osos métodos para la producción de un antígeno tal. Lapresente invención se refiere a secuencias de nucleótidos que que codifican la proteína antigénica, sus mutantes y derivados. La presente invención se refiereademás a métodos para expresarel nov edoso antígeno, inclusive vectores de expresión y cepas de células, tanto eucariotas como procariotas. La invenciónse refiere también a métodos para utilizar este novedoso antígeno en calidad de inmunógeno en preparaciones de vacunaspara la pre vención y/o tratamiento delas infecciones por HTLV-I y HTLV-II. La presente invención se refiere a una proteina de HTLV env que carece de la totalidad o de una porción de su dominioque cubre la membrana, de modo tal que elpolipéptido, al ser expr esado de manera recombinante, no es anclado en la membrana de la célula huésped. En unaforma de realización preferida de la invención, la proteína HTLV env, soluble, carece de la totalidad, o de una porción, de suterminal amino. La presenteinv ención se refiere además a una forma amino truncada de la proteína HTLV env que es soluble y se acumula en el citoplasma de la célula huésped,de manera talque la proteína HTLV env es fácilmente purificada a partir decélulas huésped lisadas.The present invention relates to novel protein antigens derived from the HTLV env protein, which are capable of being used as vaccines to aid in the prevention and treatment of HTLV-I and HTLV-II infections, and anoved methods for the production of such an antigen. The present invention refers to nucleotide sequences that encode the antigenic protein, its mutants and derivatives. The present invention further relates to methods for expressing the novel antigen, including expression vectors and cell strains, both eukaryotic and prokaryotic. The invention also relates to methods of using this novel antigen as an immunogen in vaccine preparations for the prevention and / or treatment of HTLV-I and HTLV-II infections. The present invention relates to an HTLV env protein that lacks all or a portion of its membrane-spanning domain, such that the polypeptide, when expressed recombinantly, is not anchored in the cell membrane Guest. In a preferred embodiment of the invention, the soluble HTLV env protein lacks all, or a portion, of its amino terminal. The present invention further refers to a truncated amino form of the HTLV env protein that is soluble and accumulates in the cytoplasm of the host cell, such that the HTLV env protein is readily purified from lysed host cells.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68105496A | 1996-07-22 | 1996-07-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR003102A1 true AR003102A1 (en) | 1998-07-08 |
Family
ID=24733624
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP970103292A AR003102A1 (en) | 1996-07-22 | 1997-07-22 | ENV-GLYCOPROTEIN VACCINE FOR THE PROTECTION OF HTLV-I AND II INFECTION |
Country Status (5)
| Country | Link |
|---|---|
| AR (1) | AR003102A1 (en) |
| AU (1) | AU3807397A (en) |
| BR (1) | BR9711809A (en) |
| CO (1) | CO4750675A1 (en) |
| PE (1) | PE108098A1 (en) |
-
1997
- 1997-07-22 AR ARP970103292A patent/AR003102A1/en unknown
- 1997-07-22 BR BR9711809-5A patent/BR9711809A/en not_active Application Discontinuation
- 1997-07-22 AU AU38073/97A patent/AU3807397A/en not_active Abandoned
- 1997-07-22 PE PE00065397A patent/PE108098A1/en not_active Application Discontinuation
- 1997-07-22 CO CO97041595A patent/CO4750675A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE108098A1 (en) | 1999-01-26 |
| CO4750675A1 (en) | 1999-03-31 |
| BR9711809A (en) | 2001-11-06 |
| AU3807397A (en) | 1998-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2221045C2 (en) | Haemophilus influenzae antigen omp26, nucleic acid encoding it and its using | |
| DE69829668D1 (en) | PREPARATION AND USE OF RECOMBINANT INFLUENZA A VIRUS M2 CONSTRUCTIONS AND IMPORTS | |
| DE68927348T2 (en) | ARTIFICIAL VACCINE AGAINST AIDS VIRUS | |
| DK0679187T3 (en) | Method for Extracting Native Oligomeric Glycosolated Ectodomains from Viral Membrane Proteins and Their Use, Especially as a Vaccine against HIV | |
| HUP0104889A2 (en) | Antigenic peptides derived from telomerase | |
| HUP9902438A2 (en) | Parapoxvirus vectors | |
| BR9712556A (en) | Plasmid, pharmaceutical composition, and, process of immunizing an individual against an antigen | |
| ATE355375T1 (en) | BACTERIOFERRITIN FROM HELICOBACTER PYLORI | |
| AU4826493A (en) | Anti-feline immunodeficiency virus (fiv) vaccines | |
| AU2529095A (en) | Vaccine against mycobacterial infections | |
| PT914437E (en) | IDENTIFICATION AND CLONING OF A MYCOBACTERIAL ANTIGEN CORRESPONDING TO HEMAGLUTININE FROM LIGACAO TO HEPARINA | |
| HUP9801384A2 (en) | Clostridium perfringens vaccine | |
| DK1509543T3 (en) | Non-immunosuppressive immunogen or vaccine composition comprising a mutated E7 protein from the HPV-16 virus | |
| DK35891D0 (en) | PRACTICALLY TAKEN PURE, ANTIGENIC PEPTIDE OR PROTEIN WITH AN EPITOP OF HAEMOPHILUS INFLUENZAE, ITS PREPARATION AND USE | |
| DE69935599D1 (en) | MODIFIED HCV PEPTIDE VACCINES | |
| AR003102A1 (en) | ENV-GLYCOPROTEIN VACCINE FOR THE PROTECTION OF HTLV-I AND II INFECTION | |
| PE20010237A1 (en) | GENE DERIVED FROM LAWSONIA AND OmpH POLYPEPTIDES, PEPTIDES AND RELATED PROTEINS AND THEIR USES | |
| PE20010238A1 (en) | GENE DERIVED FROM LAWSONIA AND POLYPEPTIDES SodC, PEPTIDES AND RELATED PROTEINS AND THEIR USES | |
| KR960702000A (en) | RECOMBINANT ANTIGENS FROM MUMPS VIRUS AND THEIR USE IN VACCINES | |
| PE20010316A1 (en) | GENE DERIVED FROM LAWSONIA AND RELATED POLYPEPTIDES, PEPTIDES AND PROTEINS AND THEIR USES | |
| PT840750E (en) | HA-2 ANTIGENIC PEPTID | |
| WO2023214082A3 (en) | Signal sequences for nucleic acid vaccines | |
| AR123329A1 (en) | VACCINES AGAINST COVID-19 WITH SQUALENE EMULSION ADJUVANTS CONTAINING TOCOPHEROL | |
| BR9807774A (en) | cell surface | |
| WO2001070774B1 (en) | Human t cell response to mhc-binding motif clusters |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |